{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:14:54Z","timestamp":1790194494546,"version":"4.1.0"},"reference-count":109,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T00:00:00Z","timestamp":1581379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>The number of treatment options for melanoma patients has grown in the past few years, leading to considerable improvements in both overall and progression-free survival. Targeted therapies and immune checkpoint inhibitors have opened a new era in the management of melanoma patients. Despite the clinical advances, further research efforts are needed to identify other \u201cdruggable\u201d targets and new biomarkers to improve the stratification of melanoma patients who could really benefit from targeted and immunotherapies. To this end, many studies have focused on the role of microRNAs (miRNAs) that are small non-coding RNAs (18-25 nucleotides in length), which post-transcriptionally regulate the expression of their targets. In cancer, they can behave either as oncogenes or oncosuppressive genes and play a central role in many intracellular pathways involved in proliferation and invasion. Given their modulating activity on the transcriptional landscape, their biological role is under investigation to study resistance mechanisms. They are able to mediate the communication between tumor cells and their microenvironment and regulate tumor immunity through direct regulation of the genes involved in immune activation or suppression. To date, a very promising miRNA-based strategy is to use them as prognosis and diagnosis biomarkers both as cell-free miRNAs and extracellular-vesicle miRNAs. However, miRNAs have a complex role since they target different genes in different cellular conditions. Thus, the ultimate aim of studies has been to recapitulate their role in melanoma in biological networks that account for miRNA\/gene expression and mutational state. In this review, we will provide an overview of current scientific knowledge regarding the oncogenic or oncosuppressive role of miRNAs in melanoma and their use as biomarkers, with respect to approved therapies for melanoma treatment.<\/jats:p>","DOI":"10.3390\/cells9020415","type":"journal-article","created":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T11:45:30Z","timestamp":1581421530000},"page":"415","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["miRNAs as Key Players in the Management of Cutaneous Melanoma"],"prefix":"10.3390","volume":"9","author":[{"given":"Celeste","family":"Lorusso","sequence":"first","affiliation":[{"name":"Molecular Diagnostics and Pharmacogenetics Unit, IRCCS-Istituto Tumori \u201cGiovanni Paolo II\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9607-3754","authenticated-orcid":false,"given":"Simona","family":"De Summa","sequence":"additional","affiliation":[{"name":"Molecular Diagnostics and Pharmacogenetics Unit, IRCCS-Istituto Tumori \u201cGiovanni Paolo II\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosamaria","family":"Pinto","sequence":"additional","affiliation":[{"name":"Molecular Diagnostics and Pharmacogenetics Unit, IRCCS-Istituto Tumori \u201cGiovanni Paolo II\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Danza","sequence":"additional","affiliation":[{"name":"Molecular Diagnostics and Pharmacogenetics Unit, IRCCS-Istituto Tumori \u201cGiovanni Paolo II\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Tommasi","sequence":"additional","affiliation":[{"name":"Molecular Diagnostics and Pharmacogenetics Unit, IRCCS-Istituto Tumori \u201cGiovanni Paolo II\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,2,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Ward, W.H., and Farma, J.M. (2017). Epidemiology of Melanoma. Cutaneous Melanoma: Etiology and Therapy, Codon Publications.","DOI":"10.15586\/codon.cutaneousmelanoma.2017"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1159\/000478893","article-title":"Liquid biopsy: Value for melanoma therapy","volume":"40","author":"Machiraju","year":"2017","journal-title":"Oncol. Res. Treat."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrm3838","article-title":"Regulation of microRNA biogenesis","volume":"15","author":"Ha","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.ejca.2012.11.019","article-title":"Resistance to BRAF-targeted therapy in melanoma","volume":"49","author":"Sullivan","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/107327481302000404","article-title":"Melanoma mutagenesis and aberrant cell signaling","volume":"20","author":"Bello","year":"2013","journal-title":"Cancer Control"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/ITT.S134842","article-title":"Melanoma treatment in review","volume":"7","author":"Domingues","year":"2018","journal-title":"Immuno Targets Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1146\/annurev-med-050410-105655","article-title":"Targeting Metastatic Melanoma","volume":"63","author":"Flaherty","year":"2012","journal-title":"Annu. Rev. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1038\/jid.2015.229","article-title":"Intra- and inter-tumoral homogeneity BRAFV600E mutations in melanoma tumors","volume":"135","author":"Villanueva","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-13-0642","article-title":"Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy","volume":"4","author":"Shi","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.2147\/OTT.S117121","article-title":"NRAS-mutant melanoma: Current challenges and future prospect","volume":"10","author":"Adelantado","year":"2017","journal-title":"Onco. Targets. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1470-2045(13)70024-X","article-title":"MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: A non-randomised, open-label phase 2 study","volume":"14","author":"Ascierto","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1470-2045(17)30180-8","article-title":"Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): A multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Dummer","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.2147\/DDDT.S89114","article-title":"Receptor tyrosine kinase (c-Kit) inhibitors: A potential therapeutic target in cancer cells","volume":"10","author":"Babaei","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic Classification of Cutaneous Melanoma","volume":"161","author":"Akbani","year":"2015","journal-title":"Cell"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Mishra, P.J., and Merlino, G. (2016). Integrated Genomics Identifies miR-32\/MCL-1 Pathway as a Critical Driver of Melanomagenesis: Implications for miR-Replacement and Combination Therapy. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0165102"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"E5005","DOI":"10.1073\/pnas.1607753113","article-title":"miR-579-3p controls melanoma progression and resistance to target therapy","volume":"113","author":"Fattore","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.ajpath.2012.07.009","article-title":"MiR-200c inhibits melanoma progression and drug resistance through down-regulation of Bmi-1","volume":"181","author":"Liu","year":"2012","journal-title":"Am. J. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/pcmr.12379","article-title":"miR-200c\/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment","volume":"28","author":"Liu","year":"2015","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"53558","DOI":"10.18632\/oncotarget.10669","article-title":"miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR\/IGF-1R\/CRAF and inhibiting the MAPK and PI3K\/AKT signaling pathways","volume":"7","author":"Sun","year":"2016","journal-title":"Oncotarget"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/mc.22542","article-title":"MicroRNA-21 regulates the ERK\/NF-kB signalingpathway to affect the proliferation, migration, and apoptosis of human melanoma A375 cells by targeting SPRY1, PDCD4, and PTEN","volume":"56","author":"Mao","year":"2017","journal-title":"Mol. Carcinog."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.acthis.2011.11.001","article-title":"The status of microRNA-21 expression and its clinical significance in human cutaneous malignant melanoma","volume":"114","author":"Jiang","year":"2012","journal-title":"Acta Histochem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"22262","DOI":"10.18632\/oncotarget.14763","article-title":"MicroRNAs in melanoma development and resistance to target therapy","volume":"8","author":"Fattore","year":"2017","journal-title":"Oncotarget"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.18632\/oncotarget.3070","article-title":"miR-638 promotes melanoma metastasis and protects melanoma cells from apoptosis and autophagy","volume":"6","author":"Bhattacharya","year":"2015","journal-title":"Oncotarget"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4428","DOI":"10.18632\/oncotarget.6599","article-title":"Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b","volume":"7","author":"Vergani","year":"2016","journal-title":"Oncotarget"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1517\/14728222.2015.1065818","article-title":"MicroRNA expression in BRAF-mutated and wild-type metastatic melanoma and its correlation with response duration to BRAF inhibitors","volume":"19","author":"Pinto","year":"2015","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"17753","DOI":"10.18632\/oncotarget.3924","article-title":"miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma","volume":"6","author":"Stark","year":"2015","journal-title":"Oncotarget"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/nrg3074","article-title":"Non-coding RNAs in human disease","volume":"12","author":"Esteller","year":"2011","journal-title":"Nat. Rev. Genet."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1758-907X-3-1","article-title":"Inhibition of microRNA function by antimiR oligonucleotides","volume":"3","author":"Stenvang","year":"2012","journal-title":"Silence"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ebiom.2016.09.017","article-title":"microRNA Therapeutics in Cancer\u2014An Emerging Concept","volume":"12","author":"Shah","year":"2016","journal-title":"EBioMedicine"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"9504","DOI":"10.1200\/JCO.2017.35.15_suppl.9504","article-title":"Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment","volume":"35","author":"Robert","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_38","first-page":"449","article-title":"Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma","volume":"63","author":"Kelderman","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/bjc.2017.70","article-title":"Evaluation of clinicopathological factors in PD-1 response: Derivation and validation of a prediction scale for response to PD-1 monotherapy","volume":"116","author":"Nosrati","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3389\/fonc.2017.00233","article-title":"Biomarkers for response of melanoma patients to immune checkpoint inhibitors: A systematic review","volume":"7","author":"Jessurun","year":"2017","journal-title":"Front. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/bjc.2015.467","article-title":"Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma","volume":"114","author":"Diem","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Miao","year":"2015","journal-title":"Science"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1126\/scitranslmed.aah3560","article-title":"Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance","volume":"9","author":"Roh","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/ng.3677","article-title":"Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy","volume":"48","author":"Riaz","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"103","DOI":"10.20892\/j.issn.2095-3941.2018.0006","article-title":"Key questions about the checkpoint blockade-are microRNAs an answer?","volume":"15","author":"Dragomir","year":"2018","journal-title":"Cancer Biol. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.12659\/MSM.913881","article-title":"Integrative Analysis of Long Noncoding RNA (lncRNA), microRNA (miRNA) and mRNA Expression and Construction of a Competing Endogenous RNA (ceRNA) Network in Metastatic Melanoma","volume":"25","author":"Wang","year":"2019","journal-title":"Med. Sci. Monit."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"6275","DOI":"10.1158\/0008-5472.CAN-08-4517","article-title":"MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: Potential implications for immune based therapy of human solid tumors","volume":"69","author":"Xu","year":"2009","journal-title":"Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1038\/jid.2013.114","article-title":"B7-H3 associated with tumor progression and epigenetic regulatory activity in cutaneous melanoma","volume":"133","author":"Wang","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.4049\/jimmunol.173.4.2500","article-title":"Murine B7-H3 Is a Negative Regulator of T Cells","volume":"173","author":"Prasad","year":"2004","journal-title":"J. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/ni967","article-title":"The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses","volume":"4","author":"Suh","year":"2003","journal-title":"Nat. Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11060-009-0038-7","article-title":"Compartmental intrathecal radioimmunotherapy: Results for treatment for metastatic CNS neuroblastoma","volume":"97","author":"Kramer","year":"2010","journal-title":"J. Neurooncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1002\/ijc.26238","article-title":"B7-H3 contributes to the metastatic capacity of melanoma cells by modulation of known metastasis-associated genes","volume":"130","author":"Tekle","year":"2012","journal-title":"Int. J. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.immuni.2017.11.021","article-title":"Transcription Factor IRF4 Promotes CD8+ T Cell Exhaustion and Limits the Development of Memory-like T Cells during Chronic Infection","volume":"47","author":"Man","year":"2017","journal-title":"Immunity"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1158\/2326-6066.CIR-18-0504","article-title":"MicroRNA-155 expression is enhanced by T-cell receptor stimulation strength and correlates with improved tumor control in Melanoma","volume":"7","author":"Sempere","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining \u2018T cell exhaustion\u2019","volume":"19","author":"Blank","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"6692","DOI":"10.1038\/ncomms7692","article-title":"PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation","volume":"6","author":"Patsoukis","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e1792","DOI":"10.1038\/cddis.2015.162","article-title":"T-cell exhaustion in the tumor microenvironment","volume":"6","author":"Jiang","year":"2015","journal-title":"Cell Death Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1084\/jem.20100637","article-title":"Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients","volume":"207","author":"Fourcade","year":"2010","journal-title":"J. Exp. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1158\/0008-5472.CAN-11-2637","article-title":"CD8 + T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1","volume":"72","author":"Fourcade","year":"2012","journal-title":"Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"53735","DOI":"10.18632\/oncotarget.10731","article-title":"miR-28 modulates exhaustive differentiation of T cells through silencing programmed cell death-1 and regulating cytokine secretion","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"15894","DOI":"10.18632\/oncotarget.15213","article-title":"PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p","volume":"8","author":"Audrito","year":"2017","journal-title":"Oncotarget"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1479-5876-9-44","article-title":"Differentiation associated regulation of microRNA expression in vivo in human CD8+T cell subsets","volume":"9","author":"Salaun","year":"2011","journal-title":"J. Transl. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"33744","DOI":"10.18632\/oncotarget.8164","article-title":"Unexpected positive control of NF\u03baB and miR-155 by DGKa and \u03b6 ensures effector and memory CD8+ T Cell differentiation","volume":"7","author":"Yang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1074\/jbc.M708218200","article-title":"B-cell receptor activation induces BIC\/miR-155 expression through a conserved AP-1 element","volume":"283","author":"Yin","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat. Methods"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1128\/MCB.00762-15","article-title":"MicroRNA 211 Functions as a Metabolic Switch in Human Melanoma Cells","volume":"36","author":"Mazar","year":"2016","journal-title":"Mol. Cell. Biol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrc2868","article-title":"Targeting the tumour vasculature: Insights from physiological angiogenesis","volume":"10","author":"Chung","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.cell.2012.10.028","article-title":"Convergent multi-miRNA targeting of ApoEgrives LRP1\/LRP8-dependent melanoma metastasis and angiogenesis","volume":"151","author":"Pencheva","year":"2012","journal-title":"Cell"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrc1093","article-title":"Tumorigenesis and the angiogenic switch","volume":"3","author":"Bergers","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.1158\/0008-5472.CAN-12-1383","article-title":"Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells","volume":"72","author":"Noman","year":"2012","journal-title":"Cancer Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1038\/onc.2014.294","article-title":"CSF1-ETS2-induced microRNA in myeloid cells promote metastatic tumor growth","volume":"34","author":"Mathsyaraja","year":"2015","journal-title":"Oncogene"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1158\/0008-5472.CAN-11-1977","article-title":"Tumor suppressive microRNAs miR-34a\/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D","volume":"72","author":"Heinemann","year":"2012","journal-title":"Cancer Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.3389\/fimmu.2019.01099","article-title":"Myeloid-derived suppressor cells: Not only in tumor immunity","volume":"10","author":"Pawelec","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1158\/0008-5472.CAN-14-2331","article-title":"Host miR155 promotes tumor growth through a myeloid-derived suppressor cell-dependent mechanism","volume":"75","author":"Chen","year":"2015","journal-title":"Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.4049\/jimmunol.1103505","article-title":"MicroRNA-494 Is Required for the Accumulation and Functions of Tumor-Expanded Myeloid-Derived Suppressor Cells via Targeting of PTEN","volume":"188","author":"Liu","year":"2012","journal-title":"J. Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Roche, J. (2018). The Epithelial-to-Mesenchymal Transition in Cancer. Cancers, 10.","DOI":"10.3390\/cancers10020052"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1158\/2159-8290.CD-13-0424","article-title":"A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors","volume":"4","author":"Konieczkowski","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ccr.2013.08.018","article-title":"A Switch in the Expression of Embryonic EMT-Inducers Drives the Development of Malignant Melanoma","volume":"24","author":"Caramel","year":"2013","journal-title":"Cancer Cell"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/mc.22365","article-title":"Progression of mouse skin carcinogenesis is associated with the orchestrated deregulation of mir-200 family members, mir-205 and their common targets","volume":"55","author":"Skourti","year":"2016","journal-title":"Mol. Carcinog."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/path.2964","article-title":"MicroRNA-9 up-regulates E-cadherin through inhibition of NF-\u03baB1-Snail1 pathway in melanoma","volume":"226","author":"Liu","year":"2012","journal-title":"J. Pathol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/15592294.2014.1003746","article-title":"Epigenetic regulation in human melanoma: Past and future","volume":"10","author":"Sarkar","year":"2014","journal-title":"Epigenetics"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.18632\/oncotarget.622","article-title":"Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma","volume":"3","author":"Asangani","year":"2012","journal-title":"Oncotarget"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1038\/ncomms7051","article-title":"The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors","volume":"6","author":"Zingg","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nrc3066","article-title":"Cell-free nucleic acids as biomarkers in cancer patients","volume":"11","author":"Schwarzenbach","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.semcancer.2019.01.003","article-title":"The circulating transcriptome as a source of cancer liquid biopsy biomarkers","volume":"58","author":"Sole","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.jprot.2010.06.006","article-title":"Exosomes: Extracellular organelles important in intercellular communication","volume":"73","author":"Mathivanan","year":"2010","journal-title":"J. Proteom."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Mumford, S.L., Towler, B.P., Pashler, A.L., Gilleard, O., Martin, Y., and Newbury, S.F. (2018). Circulating microRNA biomarkers in melanoma: Tools and challenges in personalised medicine. Biomolecules, 8.","DOI":"10.3390\/biom8020021"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12943-018-0757-5","article-title":"Liquid biomarkers in melanoma: Detection and discovery","volume":"17","author":"Lim","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_91","first-page":"175","article-title":"Extracellular\/Circulating MicroRNAs: Release Mechanisms, Functions and Challenges","volume":"10","author":"Sohel","year":"2016","journal-title":"Achiev. Life Sci."},{"key":"ref_92","unstructured":"Carpi, S., Polini, B., Fogli, S., Nieri, P., and Romanini, A. (2016). Circulating MicroRNAs in Cutaneous Melanoma Diagnosis and Prognosis. Manag. Malig. Melanoma., 12."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Leidinger, P., Keller, A., Borries, A., Reichrath, J., Rass, K., Jager, S.U., Lenhof, H.P., and Meese, E. (2010). High-throughput miRNA profiling of human melanoma blood samples. BMC Cancer, 10.","DOI":"10.1186\/1471-2407-10-262"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1010428317701646","DOI":"10.1177\/1010428317701646","article-title":"Identification of plasma microRNAs as new potential biomarkers with high diagnostic power in human cutaneous melanoma","volume":"39","author":"Fogli","year":"2017","journal-title":"Tumor Biol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.12659\/MSM.891327","article-title":"Circulating miR-221 expression level and prognosis of cutaneous malignant melanoma","volume":"20","author":"Li","year":"2014","journal-title":"Med. Sci. Monit."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ebiom.2015.05.011","article-title":"The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis","volume":"2","author":"Stark","year":"2015","journal-title":"EBioMedicine"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/pcmr.12755","article-title":"Circulating cell-free microRNAs in cutaneous melanoma staging and recurrence or survival prognosis","volume":"32","author":"Polini","year":"2019","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jdermsci.2010.12.010","article-title":"The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker","volume":"61","author":"Kanemaru","year":"2011","journal-title":"J. Dermatol. Sci."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/cncr.28981","article-title":"Serum-based miRNAs in the prediction and detection of recurrence in melanoma patients","volume":"121","author":"Fleming","year":"2015","journal-title":"Cancer"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/1479-5876-10-155","article-title":"Serum microRNAs as biomarkers for recurrence in melanoma","volume":"10","author":"Friedman","year":"2012","journal-title":"J. Transl. Med."},{"key":"ref_101","first-page":"3097","article-title":"Decreased serum microRNA-206 level predicts unfavorable prognosis in patients with melanoma","volume":"8","author":"Tian","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"12110","DOI":"10.18632\/oncotarget.3661","article-title":"Comparison of a healthy miRNome with melanoma patient miRNomes: Are microRNAs suitable serum biomarkers for cancer?","volume":"6","author":"Margue","year":"2015","journal-title":"Oncotarget"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/CMR.0b013e328363e485","article-title":"Sensitive detection of melanoma metastasis using circulating microRNA expression profiles","volume":"23","author":"Shiiyama","year":"2013","journal-title":"Melanoma Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/bjc.2017.477","article-title":"Development and validation of a plasmabased melanoma biomarker suitable for clinical use","volume":"118","author":"Lincoln","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Karin-Kujundzic, V., Sola, I.M., Predavec, N., Potkonjak, A., Somen, E., Mioc, P., Serman, A., Vranic, S., and Serman, L. (2019). Novel Epigenetic Biomarkers in Pregnancy-Related Disorders and Cancers. Cells, 8.","DOI":"10.3390\/cells8111459"},{"key":"ref_106","first-page":"1","article-title":"The role of extracellular vesicles: An epigenetic view of the cancer microenvironment","volume":"1","author":"Qian","year":"2015","journal-title":"Biomed Res. Int."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1476-4598-12-62","article-title":"Biochemical and biological characterization of exosomes containing prominin-1\/CD133","volume":"12","author":"Rappa","year":"2013","journal-title":"Mol. Cancer"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"828","DOI":"10.5858\/arpa.2013-0134-OA","article-title":"Study of circulating MicroRNA-125b levels in serum exosomes in advanced melanoma","volume":"138","author":"Alegre","year":"2014","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/CMR.0000000000000450","article-title":"Serum exosomal microRNAs as potent circulating biomarkers for melanoma","volume":"28","author":"Tengda","year":"2018","journal-title":"Melanoma Res."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/9\/2\/415\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T08:56:55Z","timestamp":1760173015000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/9\/2\/415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,11]]},"references-count":109,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2]]}},"alternative-id":["cells9020415"],"URL":"https:\/\/doi.org\/10.3390\/cells9020415","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,11]]}}}